Health Economics

Direct medical costs of hospitalized patients with idiopathic pulmonary fibrosis in China
Xiaofen Zheng, Bingbing Xie, Yan Liu, Ming Zhu, Shu Zhang, Chengjun Ban, Jing Geng, Dingyuan Jiang, Yanhong Ren, Huaping Dai, Chen Wang

medRxiv 19010025; doi: https://doi.org/10.1101/19010025
DyeVer PLUS EZ system for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost-Utility Analysis
Mehdi javanbakht, Mohsen Rezaie Hemami, Atefeh Mashayekhi, Michael Branagan-Harris

medRxiv 19008185; doi: https://doi.org/10.1101/19008185
A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: priority weights
Øystein Ariansen Haaland, Frode Lindemark, Kjell Arne Johansson

medRxiv 19003780; doi: https://doi.org/10.1101/19003780
Why so many significant Phase 3 results in clinical trials?
Jerome Adda, Christian Decker, Marco Ottaviani

medRxiv 19001495; doi: https://doi.org/10.1101/19001495